The present invention relates to the controlled release pharmaceutical formulation of active ingredient belonging to the class of antidepressant, in the form of oral dosage form. The active agent of the said invention is Fluoxetin and it may be present in the form of free base or pharmaceutically acceptable salt for...

The present invention relates to pharmaceutical compositions of antihistamine-decongestant combination. Specifically the invention relates to bilayered tablet formulation comprising antihistaminic decongestant combination. More specifically present invention relates to the novel polymorph of fexofenadine or pharmace...

The present invention relates to the controlled release oral tablet formulations of ibuprofen. The use of Carbopol and Kollidon SR for controlling the release of ibuprofen from the tablet offers various advantages over the polymers described in prior art. The tablets are prepared by wet granulation method and belong...

The present invention provides an improved and more efficient process for the preparation of Zaleplon of Formula (1), which comprises the condensation of 3-dimethylamino- l- (3-Nethyl-N-acetyl amino phenyl)-2-propene-1-one or suitable salt with 3-amino pyrazole-4carbonitrile or suitable salt in an aqueous mixture of...

A process for the preparation of compound of the formula (I), wherein R1 represents (C1-C6)alkyl group, which comprises: i). converting the compound of formula (II) wherein H1 represents (C1-H6)alkyl group to a compound of formula (III) by reacting with phenyl ethylamine in the ...

The present invention relates to novel anticancer agents, their derivatives, their analogs, their stereoisomers, their tautomers, their geometric isomers, their polymorphs, their phamaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutically acceptable compositions. The pres...

The present application relates to process for the preparation of prasugrel its pharmaceutically acceptable salts and its intermediates.

The present invention relates to processes for the preparation and purification of marbofloxacin.

The present invention relates to a process for the preparartion of flecainide and its salts which process in includes reducing 2,5-Bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethy)-benzamide of Formula lll in a solvent in the presence of palladium on a support carrier to obtain flecainide; and converting flecainide to i...

Abstract NOVEL OXAZOUDTNONE COMPOUNDS AS ANTIINFECTIVE AGENTS The present invention  to novel oxazolidinone compounds of (1) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomer, their prod rugs, pharmaceutical compositions comprising the same and to their use as therapeutic age...

The present invention relates to novel andrographolide compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing thein. The present inventio...

The present invention relates to processes for the preparation of marbofloxacin and its intermediate compounds.

Abstract A process for isolation of an active growth factor is described. The process uses an economic and single step method for the purification of recombinant active growth factor from the inactive forms. Additionally the process also removes host cell proteins from the crude protein mixture resulting in pure bi...

The present invention is directed to novel crystalline fonn of Rabeprazole sodium. This crystalline fonn of Rabeprazole sodium is designated as fonn Z for convenience. The present invention further provides a process for the preparation of novel crystalline form of Rabeprazole sodium, which is a commercially viabl...

The present invention is directed to provide a novel process for the preparation of Form- II of Olanzapine. The present invention also embodies the novel process for the preparation of crystalline Form-ll of Olanzapine, which comprises dissolving the Olanzapine monohydrate or Olanzapine dihydrate or Olanzapine Fonn-...

A process for preparing topotecan or a salt thereof, comprising reacting 10-hydroxy camptothecin with dimethylamine and about 1 to about 3 equivalents of formaldehyde, per equivalent of 10-hydroxy camptothecin, in the presence of acetic acid to form topotecan acetate.

A two-Stage method is proposed for producing a highly transparent anode emitter (2) in a GTO (1) . In a first step, an anode emitter (2) is indiffused whose thickness is greater than 0.5 μm and whose doping concentration is greater than 1017- cm-3. In a second step, the emitter efficiency of the anode emitter (2) is...

The present invention relates to novel pyrimidine compounds of general formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. Where all symbols are a...

The present invention related to a process for the preparation of hydroxyphenyl)-2-h drox 3 (4Y ypropionic acid of the formula (1) 3-(4-benzyloxyphenyl)-2-hydroxyphenyl acid of the formula (4) using chemical method in the presence of trifluoroacetic acid as a solvent at a temperature in the range of ...

The present invention is directed to prepare a novel crystalline polymorph form-I of valsartan and also embodies a process for the preparation of novel crystalline polymorph form-Ii of valsartan,which comprises the dissolution of cryde valsartan in ketone solvents such as ethyl ketone,methly isobutyl ketone,methlyl ...

Co-crystals comprising aripiprazole and fumaric acid.

Processes for the preparation of armodafinil crystalline Form I. Also provided is armodafinil having about 30% or more by weight of particles with sizes greater than about 250 µm, and about 70% or less by weight of particles having sizes less than about 250 µm, wherein of the particles having sizes less than about 2...

There is provided a process for the preparation of celecoxib by reacting4,4,4,-trifluoro-1-1[4-(methyl]butane-1,3-dione with 4-sulphonamidophenylhydrazine or its salt in solvent medium that contains an alkyl ester, There is also provided a process for the purification of celecoxib using aromatic hydrocarbon solven...

The present application relates to process for preparation of amorphous form of Trilaciclib dihydrochloride, and pharmaceutical compositions thereof.

enclosed